Por favor, use este identificador para citar o enlazar este ítem: http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2385
Título : Efficacy of a tetravalent dengue vaccine in children in Latin America
Creador: Villar L
Nivel de acceso: Open access
Palabras clave : Adolescente
Anticuerpos Antivirales - sangre
niño
Dengue - inmunología
Dengue - prevención & control
Dengue - virología
Vacunas contra el Dengue - inmunología
Virus del Dengue - genética
Virus del Dengue - inmunología
Virus del Dengue - aislamiento & purificación
Enfermedades Endémicas - prevención & control
Femenino
Hospitalizacion
Humanos
Análisis de Intención de Tratar
América Latina
Masculino
Serogrupo
Índice de Severidad de la Enfermedad
Método Simple-Ciego
Resultado del Tratamiento
Vacunas Atenuadas -inmunología
Adolescent
Antibodies, Viral - blood
Child
Dengue - immunology
Dengue - prevention & control
Dengue - virology
Dengue Vaccines - immunology
Dengue Virus - genetics
Dengue Virus - immunology
Dengue Virus - isolation & purification
Endemic Diseases - prevention & control
Female
Hospitalizat1ion
Humans
Intention to Treat Analysis
Latin America
Male
Serogroup
Severity of Illness Index
Single-Blind Method
Treatment Outcome
Vaccines, Attenuated - immunology
Dengue
Vacunas contra el Dengue
Anticuerpos Antivirus
Virus del Dengue
Dengue
Dengue Vaccines
Antibodies, Viral
Dengue Virus
Descripción : immunogenicity subgroup of 1944 children had seropositive status for one or more dengue serotypes. In the per-protocol population, there were 176 VCD cases (with 11,793 person-years at risk) in the vaccine group and 221 VCD cases (with 5809 person-years at risk) in the control group, for a vaccine efficacy of 60.8% (95% confidence interval [CI], 52.0 to 68.0). In the intention-to-treat population (those who received at least one injection), vaccine efficacy was 64.7% (95% CI, 58.7 to 69.8). Serotype-specific vaccine efficacy was 50.3% for serotype 1, 42.3% for serotype 2, 74.0% for serotype 3, and 77.7% for serotype 4. Among the severe VCD cases, 1 of 12 was in the vaccine group, for an intention-to-treat vaccine efficacy of 95.5%. Vaccine efficacy against hospitalization for dengue was 80.3%. The safety profile for the CYD-TDV vaccine was similar to that for placebo, with no marked difference in rates of adverse events. Conclusions The CYD-TDV dengue vaccine was efficacious against VCD and severe VCD and led to fewer hospitalizations for VCD in five Latin American countries where dengue is endemic. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01374516.) Copyright © 2015 Massachusetts Medical Society. All rights reserved.
Colaborador(es) u otros Autores: Dayan Gh
Arredondo-García JL
Rivera DM
Cunha R
Deseda C
Reynales H
Costa MS
Morales-Ramírez JO
Carrasquilla G
Rey LC
Dietze R
Luz K
Rivas E
Miranda Montoya MC
Cortés Supelano M
Zambrano B
Langevin E
Boaz M
Tornieporth N
Saville M
Noriega F; Cyd15 Study Group.
Fecha de publicación : 2015
Tipo de publicación: Artículo
Formato: pdf
Identificador del Recurso : 10.1056/NEJMoa1411037
Fuente: New England Journal of Medicine 372(2):113 - 123
URI : http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2385
Idioma: eng
Aparece en las colecciones: Artículos

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.